Mandate

Vicore Pharma Holding acquires INIM Pharma

July 03, 2018

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

Related news

Sanctions update December (part 2)

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments, following the Council’s adoption of the ninth sanction package on 16 December 2022, and an agreement as to a price cap on Russian gas.
December 30, 2022

COP27 – one step closer to climate justice

COP27 was concluded on 18 November 2022 after two weeks of negotiations in Sharm El Sheikh in Egypt with the presence of leaders and representatives from 190 countries. The 1.5 °C target was a priority item on the agenda ahead of COP27, along with the efforts to support developing countries, which are particularly vulnerable to the effects of climate change. Amongst the EU’s top priorities ahead of the conference were to accelerate the phase out of coal, as well as to abolish inefficient fossil fuel subsidies.
December 19, 2022

Sanctions update December 2022

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments as follows.
December 14, 2022